Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years

All subjects will receive a single dose of GSK Biologicals' Mencevax ACWY vaccine according to the prescribing information. Subjects will be stratified into the following age groups:

2 to 5 years 6 to 17 years > 18 years The Protocol Posting has been updated in order to comply with the FDA Amendment Act, September 2007.

• Mencevax ACWY (Biological), also known as Neisseria meningitidis serogroups A, C, W and Y vaccine: 1 subcutaneous injection.

Primary outcomes

• Number of Subjects With Severe (Grade 3) Unsolicited Adverse Events [During the 31-day (Days 0-30) post-vaccination period]: An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Grade 3 AE = an AE which prevented normal, everyday activities.

Secondary outcomes

• Number of Subjects With Any and Grade 3 Solicited Local Adverse Events [During the 4-day (Days 0-3) post-vaccination period]: Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 30 millimeters (mm) of injection site (Mencevax ACWY 2-5 YOA Group) and beyond 50 millimeters (mm) of injection site (Mencevax ACWY 6-17 YOA Group and Mencevax ACWY ≥ 18 YOA Group).
• Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms [During the 4-day (Days 0-3) post-vaccination period]: Assessed solicited general symptoms were drowsiness, fever \[defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], irritability and loss of appetite. Any = occurrence of the symptom regardless of intensity grade. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 fever = fever > 39.0 °C. Grade 3 irritability = crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite = not eating at all. Related = symptom assessed by the investigator as related to the vaccination.
• Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms [During the 4-day (Days 0-3) post-vaccination period]: Assessed solicited general symptoms were fatigue, fever \[defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], gastrointestinal symptoms and headache. Any = occurrence of the symptom reported irrespective of intensity grade and causal relationship to vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
• Number of Subjects With Unsolicited Adverse Events (AEs) [During the 31-day (Days 0-30) post-vaccination period]: An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
• Number of Subjects With Serious Adverse Events (SAEs) [During the entire study period (from Day 0 to Month 1)]: SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Sex: All, ages: 2 Years to any, accepts healthy volunteers

Inclusion Criteria:

* Subjects who the investigator believes that they and/or their parent/guardian can and will comply with the requirements of the protocol.
* A Filipino male or female > 2 years of age at the time of the first vaccination.
* Free of obvious health problems as established by medical history and clinical examination before entering into the study.
* Written informed consent obtained from the subject and/or from the parent/ guardian of the subject.

Exclusion criteria:

* Subjects suffering from acute severe febrile illness.
* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
* Major congenital defects or serious chronic illness.
* History of any neurologic disorders or seizures.
* Pregnant or lactating female.
* Female planning to become pregnant.
* History of chronic alcohol consumption and/or intravenous drug abuse.
* Any contraindications as stated on the Prescribing Information.

Participant flow

Outcome results

• Number of Subjects With Severe (Grade 3) Unsolicited Adverse Events (Primary), Count of participants, Participants: Mencevax ACWY 2-5 YOA Group 0; Mencevax ACWY 6-17 YOA Group 0; Mencevax ACWY ≥ 18 YOA Group 0
• Number of Subjects With Any and Grade 3 Solicited Local Adverse Events (Secondary), Count of participants, Participants: Mencevax ACWY 2-5 YOA Group 18; Mencevax ACWY 6-17 YOA Group 10; Mencevax ACWY ≥ 18 YOA Group 9
• Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms (Secondary), Count of participants, Participants: Mencevax ACWY 2-5 YOA Group 7
• Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms (Secondary), Count of participants, Participants: Mencevax ACWY 6-17 YOA Group 1; Mencevax ACWY ≥ 18 YOA Group 0
• Number of Subjects With Unsolicited Adverse Events (AEs) (Secondary), Count of participants, Participants: Mencevax ACWY 2-5 YOA Group 14; Mencevax ACWY 6-17 YOA Group 9; Mencevax ACWY ≥ 18 YOA Group 1
• Number of Subjects With Serious Adverse Events (SAEs) (Secondary), Count of participants, Participants: Mencevax ACWY 2-5 YOA Group 0; Mencevax ACWY 6-17 YOA Group 0; Mencevax ACWY ≥ 18 YOA Group 0

Adverse events

Time frame: Solicited local and general symptoms: during the 4-day (Days 0-3) post-vaccination period; Unsolicited AEs: during the 31-day (Days 0-30) post-vaccination period; SAEs: during the entire study period (from Day 0 to Month 1).

Other adverse events by term

• GSK Clinical Trials, Study director, GlaxoSmithKline